A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma
Phase 3
Completed
- Conditions
- Glaucoma, Angle-ClosureOcular Hypertension
- Registration Number
- NCT00051181
- Lead Sponsor
- Alcon Research
- Brief Summary
To demonstrate that the intraocular pressure(IOP)-lowering efficacy of Travoprost (0.004%) is equal or better than that of Latanoprost 0.005% in patients with chronic angle-closure glaucoma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms differentiate Travoprost and Latanoprost in reducing IOP in chronic angle-closure glaucoma?
How does Travoprost 0.004% compare to Latanoprost 0.005% in long-term IOP control for angle-closure glaucoma patients?
Which biomarkers correlate with response to Travoprost or Latanoprost in chronic angle-closure glaucoma treatment?
What are the adverse event profiles of Travoprost 0.004% versus Latanoprost 0.005% in Phase 3 trials for angle-closure glaucoma?
Are there combination therapies involving Travoprost or Latanoprost that improve outcomes in chronic angle-closure glaucoma?
Trial Locations
- Locations (2)
Asia
🇺🇸Fort Worth, Texas, United States
Australia
🇦🇺Sidney, Australia
Asia🇺🇸Fort Worth, Texas, United States